Leading health and life sciences lawyers Brian Carey and Erik Schulwolf join Hogan Lovells' Boston office

“With Brian and Erik’s experience in health and life sciences, they will bolster the firm’s strategic capabilities in regulatory policy and transactional matters in these rapidly evolving sectors,” said Janice Hogan, Practice Group Leader for the Global Regulatory & Intellectual Property, Media, and Technology (IPMT) group. “Their additions further solidify our firm’s standing as a top-tier advisor in health and life sciences.”

Carey has more than 20 years of experience advising innovative life sciences companies and health care providers on federal, legal, regulatory and legislative issues affecting cutting-edge technologies. He guides biopharma and medical technology firms through intricate Medicare coverage and payment challenges, as well as compliance considerations for novel innovations.

He is a prominent advocate for technology developers and medical trade associations before the U.S. Department of Health and Human Services, the Centers for Medicare & Medicaid Services, and Congress. His guidance is instrumental for investors evaluating regulatory risks and opportunities associated with emerging technologies.

Over the past decade, he has provided strategic counsel to top clinical laboratory and molecular diagnostic companies regarding the shifting regulatory and reimbursement landscapes for Laboratory Developed Tests (LDTs) with a focus on the Protecting Access to Medicare Act of 2014. His background in health care policy includes having served as a legislative aide to Senator Edward M. Kennedy, where he contributed to health care, biotechnology, and drug legislation.

Schulwolf focuses on advising molecular diagnostic laboratories and diagnostic test manufacturers on reimbursement, compliance, and other legal matters related to precision medicine diagnostics. He advocates for clients with federal and state agencies and with private payers.

He also provides strategic advice to biopharma manufacturers and providers, focusing on the intersection of federal and state-level policy and market access issues. He has considerable experience developing reimbursement strategies, preparing advocacy approaches with state and federal agencies (in particular, CMS), and drafting federal and state legislation.

“We’ve been looking for the right fit to expand our Health practice into the key Boston market. With their combined extensive experience guiding leading life sciences companies through their most challenging regulatory, coverage and reimbursement hurdles and other compliance and policy issues, Brian and Erik are excellent additions to our team,” said Health Practice Area Leader Ron Wisor.

Carey said: “After two decades of working alongside a number of Hogan Lovells reimbursement attorneys on innovative life sciences reimbursement matters, I am excited to join the Hogan Lovells team and be part of one of the leading global life sciences regulatory and reimbursement practices.”

Schulwolf added: “With our experience advising innovative clients on the reimbursement issues involved with getting new products and technology to market, we are excited to combine our practice with the deep experience of Hogan Lovells in regulatory and compliance issues nationally and internationally.”

“We are really happy to welcome Brian and Erik to our Boston office,” said Boston Office Managing Partner Greg Noonan. “Their experience complements our growing transactional life sciences practice here.”

Brian earned his J.D. from Boston College Law School, as his bachelor’s degrees from the University of Pennsylvania and the Wharton School of Business.

Erik earned his J.D. from Harvard Law School and his bachelor’s degree from Amherst College.